1. Scrip
  2. >>Business

Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?

 
• By Anju Ghangurde

Dr Reddy’s has had a record number of US launches in Q3 with potentially more in store and now a new US CEO to steer things through, improving outlook for a significant revival in earnings. But risks of delays and competition in certain key anticipated launches in 2019 could dull prospects.

Game changer
DR REDDY'S INTRODUCED RECORD NUMBER OF PRODUCTS IN US IN Q3 • Source: Shutterstock

Dr. Reddy's Laboratories Ltd.'s third quarter earnings have been generally staid, but a record number of generic launches in the US and management commentary of an overall uptrend alongside significant cost control measures could potentially enthuse investors.

The Hyderabad-based company launched 10 new products in Q3 in the US, including colesevalam, sevelamer sachet and unit dose, aspirin and dipyridamole XR and omeprazole OTC tabs, and appears upbeat about the potential and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.